Concepedia

Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies

Paula M. Fracasso, Luis Carbajal Rodríguez, Thomas J. Herzog, Carole L. Fears, Sherry A. Goodner, Ramaswamy Govindan, Joel Picus, Janet S. Rader, Benjamin Tan, Matthew A. Arquette

Cancer · 2003 · 15 citations · 18 references

DOIFull text

Open access

Abstract

The recommended sequence and dose is 20 mg/m(2) PEG-LD followed by 40 mg/m(2) docetaxel on Days 1 and 15 of a 28-day cycle in Phase II trials for patients with breast and ovarian carcinoma to establish the efficacy of this well tolerated regimen.

References

18

Risk Factors for Doxorubicin-lnduced Congestive Heart Failure

Daniel D. Von Hoff · Annals of Internal Medicine · 1979 · 2.4K citations

, , +13

Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

Donald W. Northfelt, Bruce J. Dezube, James Thommes et al. · Journal of Clinical Oncology · 1998 · 639 citations

, , +13

Accelerated Titration Designs for Phase I Clinical Trials in Oncology

Richard Simon, Larry Rubinstein, Susan G. Arbuck et al. · JNCI Journal of the National Cancer Institute · 1997 · 632 citations · Full text

Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2

Tamar Safra, Franco M. Muggia, Susan Jeffers et al. · Annals of Oncology · 2000 · 611 citations

, , +8

Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy

Alberto Gabizón · Cancer Investigation · 2001 · 562 citations

, , +16